RecruitingPhase 1NCT03778814

TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors

TCR-T Cells Targeting Cancer Cells for Immunotherapy of Lung Cancer and Other Solid Tumors: Phase I Clinical Trial

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Enrollment

30 participants

Start Date

Dec 1, 2018

Study Type

INTERVENTIONAL

Conditions

Solid Tumor, Adult Nonsmall Cell Lung Cancer

Summary

Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the TCR-T cell immunotherapy on human will firstly be assessed.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a new type of immunotherapy for lung cancer and other solid tumors, using specially engineered immune cells called TCR-T cells. These are your own immune cells that have been modified in a lab to recognize and attack cancer cells more effectively. **You may be eligible if...** - You have advanced lung cancer or another solid tumor where a biopsy can be safely taken - Your expected survival is more than 12 weeks - Your liver is functioning adequately (Child-Pugh score below 7) - Your heart, lungs, liver, and kidneys are working reasonably well - Lab results show that your modified immune cells meet the required activity level **You may NOT be eligible if...** - Your tumor cannot be safely biopsied - You have severe organ dysfunction - Your immune cells do not meet the required potency threshold after processing Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.